Kaskela Law LLC is investigating Quidel Corporation (NASDAQ: QDEL) (“Quidel”) on behalf of the Company’s shareholders.
On December 23, 2021, Quidel announced that it had entered into a definitive agreement to acquire Ortho Clinical Diagnostics Holdings plc (“Ortho”) in a cash and stock transaction valued at $6 billion. According to the announcement, Ortho stockholders are expected to receive $24.68 per share ($7.14 in cash and 0.1055 shares of common stock in the combined company) for their Ortho shares, a 25% premium, and are expected to own approximately 38% of the combined company.
Following this announcement, shares of Quidel’s common stock declined $28.85 per share, or over 17% in value, to close on December 23, 2021 at $137.39 per share.
The investigation seeks to determine whether Quidel and/or the company’s officers and directors violated the securities laws and/or breached their fiduciary duties to QDEL shareholders in connection with the proposed transaction, and whether Quidel shareholders have been harmed as a result.
Quidel shareholders are encouraged to contact Kaskela Law LLC (David Seamus Kaskela, Esq.) at (484) 258 – 1585, or by completing the information form on this page, to receive additional information about this investigation and their legal rights and options.